Yamamoto K, Akbar S M, Masumoto T, Onji M
Third Department of Internal Medicine, Ehime University School of Medicine, Japan.
Clin Exp Immunol. 1998 Oct;114(1):94-101. doi: 10.1046/j.1365-2249.1998.00696.x.
The levels of blastogenesis in allogeneic MLR containing T cells from one normal volunteer and irradiated dendritic cells from 29 patients with PBC, 17 patients with chronic hepatitis type C (CH-C) and 22 allogeneic normal controls were compared to see if there is any role of antigen-presenting cells (APC) in the pathogenesis of PBC. The stimulatory capacity of dendritic cells from PBC was significantly lower compared with that of dendritic cells from CH-C (P < 0.05) and normal controls (P < 0.05), which could not be attributable either to the levels of expression of surface molecules, such as HLA-DR and CD86 on dendritic cells, or to the levels of cytokines, such as IL-10 and IL-12. Significantly higher levels of NO were seen in the allogeneic MLR supernatants containing dendritic cells from PBC compared with the supernatants from cultures containing dendritic cells from CH-C (P < 0.001) or normal controls (P < 0.001). Moreover, dendritic cells from PBC produced 10 times more NO compared with dendritic cells from CH-C and normal controls (21.9 +/- 2.8 microM versus 1.6 +/- 0.3 microM and 1.6 +/- 0.3 microM, respectively; P < 0.001). The addition of N(G)-monomethyl-L-arginine monoacetate (L-NMMA), a known inhibitor of NO in allogeneic MLR containing dendritic cells from PBC, resulted in a significant decrease of NO and increase of blastogenesis. The selective impairment of dendritic cell function, increased production of NO by dendritic cells and restoration of blastogenesis using NO inhibitor in PBC have suggested a role for NO and dysfunction of dendritic cells in the pathogenesis of PBC. This inspires optimism that modulating the function of dendritic cells and controlling NO production, an improved therapeutic approach, might be planned for PBC.
比较了含有一名正常志愿者的T细胞以及29例原发性胆汁性肝硬化(PBC)患者、17例丙型慢性肝炎(CH-C)患者的经辐照树突状细胞和22例同种异体正常对照的同种异体混合淋巴细胞反应(MLR)中的母细胞形成水平,以观察抗原呈递细胞(APC)在PBC发病机制中是否起作用。与CH-C患者的树突状细胞(P < 0.05)和正常对照(P < 0.05)相比,PBC患者的树突状细胞的刺激能力显著降低,这既不能归因于树突状细胞表面分子如HLA-DR和CD86的表达水平,也不能归因于细胞因子如IL-10和IL-12的水平。与含有CH-C患者树突状细胞的培养上清液(P < 0.001)或正常对照(P < 0.001)相比,含有PBC患者树突状细胞的同种异体MLR上清液中NO水平显著更高。此外,与CH-C患者和正常对照的树突状细胞相比,PBC患者的树突状细胞产生的NO多10倍(分别为21.9±2.8微摩尔/升对1.6±0.3微摩尔/升和1.6±0.3微摩尔/升;P < 0.001)。在含有PBC患者树突状细胞的同种异体MLR中加入已知的NO抑制剂N(G)-单甲基-L-精氨酸单乙酸盐(L-NMMA),导致NO显著减少,母细胞形成增加。PBC中树突状细胞功能的选择性损害、树突状细胞NO产生增加以及使用NO抑制剂恢复母细胞形成提示了NO和树突状细胞功能障碍在PBC发病机制中的作用。这激发了人们的乐观情绪,即针对PBC可能规划一种改进的治疗方法,即调节树突状细胞的功能并控制NO的产生。